HUP9904092A2 - Gyógyszerkészítmény HIV és rák kezelésére valamint eljárás előállítására - Google Patents

Gyógyszerkészítmény HIV és rák kezelésére valamint eljárás előállítására

Info

Publication number
HUP9904092A2
HUP9904092A2 HU9904092A HUP9904092A HUP9904092A2 HU P9904092 A2 HUP9904092 A2 HU P9904092A2 HU 9904092 A HU9904092 A HU 9904092A HU P9904092 A HUP9904092 A HU P9904092A HU P9904092 A2 HUP9904092 A2 HU P9904092A2
Authority
HU
Hungary
Prior art keywords
cancer
producing
pharmaceutical composition
treatment hiv
hiv
Prior art date
Application number
HU9904092A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of HUP9904092A2 publication Critical patent/HUP9904092A2/hu
Publication of HUP9904092A3 publication Critical patent/HUP9904092A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány HIV és egyéb vírűsfertőzések kezelésére szőlgáló,hatóanyagként egy herbicidet vagy fűngicidet, illetve herbicid- vagyfűngicidszármazékőt tartalmazó gyógyszerkészítményekre vőnatkőzik. Afűngicidek vagy herbicidek a HIV kezelésére alkalmas egyébhatóanyagőkkal, példáűl AZT-vel vagy prőteáz inhibitőrőkkal együtt isfelhasználhatók. ŕ
HU9904092A 1997-05-16 1997-11-26 Pharmaceutical composition for treatment hiv and cancer and process for producing it HUP9904092A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16

Publications (2)

Publication Number Publication Date
HUP9904092A2 true HUP9904092A2 (hu) 2000-04-28
HUP9904092A3 HUP9904092A3 (en) 2000-07-28

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904092A HUP9904092A3 (en) 1997-05-16 1997-11-26 Pharmaceutical composition for treatment hiv and cancer and process for producing it

Country Status (19)

Country Link
EP (1) EP0954309A1 (hu)
JP (1) JP2000510156A (hu)
KR (1) KR20000049064A (hu)
CN (1) CN1254281A (hu)
AR (1) AR009968A1 (hu)
AU (1) AU7402998A (hu)
BR (1) BR9712981A (hu)
CA (1) CA2268848A1 (hu)
CO (1) CO5070657A1 (hu)
CZ (1) CZ124999A3 (hu)
HU (1) HUP9904092A3 (hu)
IL (1) IL129351A0 (hu)
NO (1) NO991701L (hu)
PE (1) PE11499A1 (hu)
PL (1) PL335160A1 (hu)
SK (1) SK46999A3 (hu)
TR (1) TR199901530T2 (hu)
WO (1) WO1998051303A1 (hu)
ZA (1) ZA979095B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
CA2362047A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
JP2002537328A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス，インコーポレイテッド ホルモン感受性癌の治療レジメ
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001286744A1 (en) * 2000-08-25 2002-03-04 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1330441A2 (en) * 2000-09-26 2003-07-30 The University of Arizona Foundation Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
PT1830847E (pt) 2004-12-06 2015-02-05 Pitney Pharmaceuticals Pty Ltd Tratamento para o cancro
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
CN105418711A (zh) * 2015-11-06 2016-03-23 山东大学 一种α-L-鼠李糖苷酶在制备羟基脲糖苷衍生物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286412B6 (en) * 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
WO1996032104A1 (en) * 1995-04-12 1996-10-17 The Procter & Gamble Company A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
AU711966B2 (en) * 1995-08-04 1999-10-28 Procter & Gamble Company, The Use of fluconazole for inhibiting the growth of cancers

Also Published As

Publication number Publication date
PL335160A1 (en) 2000-04-10
IL129351A0 (en) 2000-02-17
SK46999A3 (en) 2000-05-16
EP0954309A1 (en) 1999-11-10
TR199901530T2 (xx) 1999-10-21
JP2000510156A (ja) 2000-08-08
CO5070657A1 (es) 2001-08-28
CN1254281A (zh) 2000-05-24
NO991701L (no) 2000-01-17
ZA979095B (en) 1998-05-11
AR009968A1 (es) 2000-05-17
PE11499A1 (es) 1999-03-01
HUP9904092A3 (en) 2000-07-28
KR20000049064A (ko) 2000-07-25
WO1998051303A1 (en) 1998-11-19
CZ124999A3 (cs) 1999-09-15
NO991701D0 (no) 1999-04-09
BR9712981A (pt) 2000-04-18
AU7402998A (en) 1998-12-08
CA2268848A1 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
HUP9904092A2 (hu) Gyógyszerkészítmény HIV és rák kezelésére valamint eljárás előállítására
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BG103786A (bg) Състав и метод за профилактика и лечение на нiv и други инфекциозни заболявания при човека
BG100455A (en) Hiv protease inhibitors
NO303540B1 (no) Sulfonylalkanoylamino-hydroksyetylaminosulfonamider som er nyttige som retrovirale proteaseinhibitorer, farmas°ytiske preparater inneholdende forbindelsene samt anvendelse av forbindelsene for fremstilling av medikamenter
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
HUP0002196A2 (hu) Gyógyhatású táplálékkiegészítő cukorbetegek részére
ES2145913T3 (es) Inhibidores de metaloproteasas.
NO905428L (no) Fremgangsmaate for fremstilling av hiv-proteaseinhibitorerfor behandling av aids.
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
DK0973735T3 (da) Polyaromatiske antivirale præparater
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
SE9604348D0 (sv) Användning av hydroxyguanidiner
HUP0400865A2 (hu) Hatóanyag-kombinációt tartalmazó készítmények szenvedély- vagy kábítószer-betegségek kezelésére és eljárás a készítmények előállítására
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO2000041463A3 (en) Combination of hepatitis b vaccine with antiviral agents